Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, Leport C, Peytavin G, Vilde JL. Duval X, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2002 Feb;46(2):570-4. doi: 10.1128/AAC.46.2.570-574.2002. Antimicrob Agents Chemother. 2002. PMID: 11796381 Free PMC article.
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Joly V, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004. Antimicrob Agents Chemother. 2004. PMID: 14693536 Free PMC article.
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. Marcelin AG, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2005 May;49(5):1720-6. doi: 10.1128/AAC.49.5.1720-1726.2005. Antimicrob Agents Chemother. 2005. PMID: 15855487 Free PMC article. Clinical Trial.
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, Blanchet F, Peytavin G, Leport C. Essig M, et al. Among authors: peytavin g. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):256-8. doi: 10.1097/QAI.0b013e3181142f31. J Acquir Immune Defic Syndr. 2007. PMID: 17895770 No abstract available.
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Desbois D, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8. doi: 10.1128/AAC.01284-07. Epub 2008 Jan 28. Antimicrob Agents Chemother. 2008. PMID: 18227188 Free PMC article.
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. Among authors: peytavin g. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group. Descamps D, et al. Among authors: peytavin g. J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13. J Antimicrob Chemother. 2008. PMID: 18552344
Occult hepatitis B in HIV-HCV coinfected patients.
Piroth L, Lafon ME, Binquet C, Bertillon P, Gervais A, Lootvoet E, Lang JM, De Jaureguiberry JP, Chene G, Leport C; ANRS CO8 APROCO-COPILOTE Study Group. Piroth L, et al. Scand J Infect Dis. 2008;40(10):835-9. doi: 10.1080/00365540801918511. Scand J Infect Dis. 2008. PMID: 18609222
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V. Marcelin AG, et al. Among authors: peytavin g. Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625773 Free PMC article.
498 results